Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis

被引：0

作者：

Bhatia, Neal ^{[1
]}

Vasquez, J. Gabriel ^{[2
]}

Schenkel, Brad

Rozzo, Stephen J. ^{[3
]}

Heim, Jayme ^{[2
]}

机构：

[1] Therapeut Clin Res, San Diego, CA USA

[2] West Michigan Dermatol, Grandville, MI USA

[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB216 / AB216

页数：1

共 50 条

[31] Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study
Puig, L.
Dauden, E.
Cuervas-Mons, M.
Novella, C.
Guisado, C.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023,
[32] Interim analysis of a real-world retrospective multicenter study: Evaluation of effectiveness of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China
Liu, N.
Xiao, X.
Pan, R.
Li, W.
Yang, B.
Shi, Y.
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S69 - S69
[33] Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis
Armstrong, April
Levi, Eugenia
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (12) : 1240 - 1245
[34] Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety
Asawanonda, Pravit
Pattamadilok, Bensachee
Chularojanamontri, Leena
Chuamanochan, Mati
Choonhakarn, Charoen
Chakkavittumrong, Panlop
Sangob, Naruemon
Rajatanavin, Natta
[J]. DERMATOLOGIC THERAPY, 2022, 35 (12)
[35] Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
Gonulal, Melis
Altunay, Ilknur Kivanc
Dogan, Sinan
Turkmen, Meltem
Balci, Didem Didar
Ozturkcan, Serap
[J]. DERMATOLOGIC THERAPY, 2022, 35 (12)
[36] PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
La Rosa, Carmen
[J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 22
[37] Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
Armstrong, April W. W.
Fitzgerald, Timothy
McLean, Robert R. R.
Teeple, Amanda
Uy, Jonathan P. P.
Olurinde, Mobolaji
Rowland, Katelyn
Guo, Lin
Shan, Ying
Duffin, Kristina Callis
[J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 629 - 640
[38] Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study
Li, Ying
Lv, Chengzhi
Dang, Lin
Lin, Bingjiang
Tao, Juan
Zhang, Chunlei
Zhou, Xiaoyong
Ma, Han
Lu, Yi
Chen, Rong
Li, Jinnan
Dou, Guanshen
Liang, Yunsheng
Liang, Yanhua
Shi, Yuling
[J]. DERMATOLOGY AND THERAPY, 2024, 14 (04) : 907 - 918
[39] Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study
Ying Li
Chengzhi Lv
Lin Dang
Bingjiang Lin
Juan Tao
Chunlei Zhang
Xiaoyong Zhou
Han Ma
Yi Lu
Rong Chen
Jinnan Li
Guanshen Dou
Yunsheng Liang
Yanhua Liang
Yuling Shi
[J]. Dermatology and Therapy, 2024, 14 : 907 - 918
[40] Cost-effectiveness of tildrakizumab in U. S. patients with moderate-to-severe plaque psoriasis
Jia, Xiaoying
Zhao, Yang
Carrico, Justin
Brodtkorb, Thor-Henrik
Mendelsohn, Alan
Lowry, Simon
Feldman, Steve R.
Wu, Jashin J.
Armstrong, April
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB39 - AB39

← 1 2 3 4 5 →